Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

60275 1492790397HCLSReviewGreeceApril2017.pdf
Energy Boardroom

GSK spin-out Convergence considers all options after positive face pain data

16.06.2014 / Scripintelligence

Convergence Pharmaceuticals has reported positive data from a Phase II trial of novel sodium channel blocker CNV1014802 in patients with trigeminal neuralgia (TGN), a very severe form of facial pain.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: